Home › Sickle Cell Disease › California › Orange
Sickle Cell Disease clinical trials in Orange, CA
3 studies for Sickle Cell Disease are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RecruitingPhase 3
- Ctr for Inherited Blood Disorders, Orange
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
RecruitingPhase 2
- University of California Irvine, Orange
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
RecruitingPhase 2
- University of California Irvine, Orange
About Sickle Cell Disease
Sickle cell disease is a group of inherited disorders that affect your red blood cells. It can cause pain, anemia, and other problems. Learn about treatments.
More about Sickle Cell Disease on MedlinePlus
Sickle Cell Disease trials in other cities
- Washington, DC21 studies
- Atlanta, GA20 studies
- Memphis, TN19 studies
- Chicago, IL18 studies
- New York City, NY16 studies
- Philadelphia, PA15 studies
- Birmingham, AL14 studies
- Houston, TX12 studies
- Boston, MA12 studies
- St. Louis, MO12 studies
- Durham, NC10 studies
- Cincinnati, OH10 studies
Other studies in Orange
- Non-Small Cell Lung Cancer28 studies
- Metastatic Cancer21 studies
- Ovarian Cancer16 studies
- Colorectal Cancer16 studies
- Cancer (all types)15 studies
- Pancreatic Cancer15 studies
- Lung Cancer15 studies
- Liver Cancer (Hepatocellular Carcinoma)14 studies
- Melanoma14 studies
- Major Depressive Disorder13 studies
- Stomach Cancer13 studies
- Prostate Cancer13 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.